EGFR and non-small cell lung carcinoma: EGFR-TKIs remain the most important targeted drugs for NSCLC patients with EGFR-sensitive mutations and have been recommended, for a number of years, as the standard first-line treatment for these patients by the National Comprehensive Cancer Network [4].